Revelation Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Revelation Biosciences wird voraussichtlich ein Umsatzwachstum verzeichnen at 79.9% per annum.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.6%
Wachstumsrate der Einnahmen	79.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	13 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Revelation Biosciences: Therapeutics And Diagnostics For Respiratory Viral Infections

Mar 28

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:REVB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	N/A	N/A	N/A	1
12/31/2025	N/A	N/A	N/A	N/A	2
12/31/2024	N/A	N/A	N/A	N/A	2
3/31/2024	N/A	-9	-9	-9	N/A
12/31/2023	N/A	0	-7	-7	N/A
9/30/2023	N/A	1	-6	-6	N/A
6/30/2023	N/A	2	-6	-6	N/A
3/31/2023	N/A	2	-8	-8	N/A
12/31/2022	N/A	-11	-11	-11	N/A
9/30/2022	N/A	-13	-13	-13	N/A
6/30/2022	N/A	-15	-14	-14	N/A
3/31/2022	N/A	-16	-14	-14	N/A
12/31/2021	N/A	-12	-11	-11	N/A
9/30/2021	N/A	-11	-10	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von REVB über der Sparquote liegt (2.4%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von REVB schneller wachsen werden als der Markt US

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von REVB in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: REVB wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: REVB wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von REVB in 3 Jahren voraussichtlich hoch sein wird

Revelation Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 93% to US$11.45

Price target decreased to US$5.00

Price target decreased to US$9.00

Recent updates

Revelation Biosciences, Inc. Has Completed Dosing of Its First in Human Phase 1 Clinical Study of Gemini

Revelation Biosciences, Inc., Annual General Meeting, May 15, 2024

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini

Revelation Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $6.183326 million.

Investor sentiment deteriorates as stock falls 19%

New major risk - Share price stability

Revelation Biosciences Announces Reverse Stock Split to Regain Compliance

Revelation Biosciences, Inc. has filed a Follow-on Equity Offering.

New minor risk - Share price stability

Revelation Biosciences Inc. Announces Data from Recent Preclinical Studies of the Gemini Formulation Demonstrates Its Therapeutic Potential as A Preventative Therapy Across Multiple Indications Including Infection and Acute Kidney Injury

Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla to Board of Directors

Price target decreased by 93% to US$11.45

Revelation Biosciences Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for its Common Stock

Revelation Biosciences, Inc. announced delayed 10-Q filing

Revelation Biosciences, Inc., Annual General Meeting, Jun 09, 2023

Independent Chairman recently bought US$60k worth of stock

Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300

High number of new and inexperienced directors

Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model

Price target decreased to US$5.00

Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease

Revelation Biosciences surges 46% on licensing deal with Vanderbilt University

Revelation Biosciences GAAP EPS of -$0.12

Revelation Biosciences stock slides 47% on pricing $5M securities offering

Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

Revelation Biosciences, Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

Price target decreased to US$9.00

Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

Revelation Biosciences Receives Non-Compliance Letter from Nasdaq

Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis

Revelation Biosciences, Inc. announced delayed annual 10-K filing

Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection

Revelation Biosciences: Therapeutics And Diagnostics For Respiratory Viral Infections

Chairman recently bought US$133k worth of stock

Chairman recently bought US$128k worth of stock

Revelation Biosciences, Inc. announced that it expects to receive $7.598001 million in funding

Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2B Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection

Revelation Biosciences Inc. Announces Enroll and Dose First Patient in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis

No independent directors

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken